Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 14 clinical trials
Featured trial
A Randomized, Open Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® with DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

A Randomized, Open Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® with DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  • 658 views
  • 08 Nov, 2020
  • 5 locations
Trabectedin for Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma

The objective of this study is to facilitate access to trabectedin for eligible previously treated subjects with soft tissue sarcoma (STS), who cannot be expected to benefit from

soft tissue sarcoma
metastatic soft tissue sarcoma
trabectedin
  • 60 views
  • 07 Nov, 2020
  • 1 location
Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor (STRADA)

Phase II randomized study for the comparison of trabectedin versus doxorubicin plus dacarbazine in patients with advanced solitary fibrous tumor

  • 33 views
  • 03 Mar, 2022
  • 5 locations
SARC037: A Phase I Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients

This study evaluates the trabectedin and irinotecan in the treatment of Ewings sarcoma, with a EWS-FLI1 mutation. Patients will also receive an infusion of 18F-FLT in combination with a Positron

refractory ewing sarcoma
irinotecan
measurable disease
  • 0 views
  • 12 May, 2021
  • 4 locations
Randomized Trial in Advanced Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.

Phase II study in patient with advanced Soft Tissue Sarcoma (STS) patients who have already received or are not suitable, for a doxorubicin-based treatment.

  • 0 views
  • 07 Nov, 2021
  • 15 locations
Metronomic Trabectedin Gemcitabine and Dacarbazine for Leiomyosarcoma

This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.

gemcitabine
trabectedin
measurable disease
leiomyosarcoma
kidney function tests
  • 0 views
  • 24 Sep, 2021
  • 1 location
Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma (TNT)

This is a Phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin as first, second or third line therapy for advanced sarcoma, including desmoid tumor and chordoma.

advanced sarcoma
trabectedin
metastatic sarcoma
measurable disease
kidney function tests
  • 37 views
  • 08 Feb, 2022
  • 1 location
Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS)

Phase I-II trial that combines trabectedin plus radiotherapy for tumor reduction response measure in two cohorts of patients: Cohort A: Patients with diagnosis of non-operable or

mpnst
liposarcoma
undifferentiated pleomorphic sarcoma
myxoid liposarcoma
cancer chemotherapy
  • 25 views
  • 17 Jun, 2022
  • 13 locations
Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors (NCT-PMO-1603)

Evaluation of the efficacy of the combination of olaparib and trabectedin in adult patients with locally advanced/metastatic solid tumors that failed standard treatment and whose molecular

  • 3 views
  • 24 Mar, 2022
  • 7 locations
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

This phase II trial studies how well trabectedin and olaparib work in treating patients with sarcoma that cannot be removed by surgery or has spread to other places in the body. Drugs used in

metastatic sarcoma
tumor cells
leiomyosarcoma
measurable disease
stromal tumor
  • 4 views
  • 01 Mar, 2022
  • 1 location